Worldwide Prostate Cancer Epidemiology: Differences Between Regions, Races, and Awareness Programs
International Journal of Clinical and Experimental Medical Sciences
Volume 2, Issue 1, January 2016, Pages: 1-6
Received: Dec. 17, 2015;
Accepted: Dec. 23, 2015;
Published: Jan. 29, 2016
Views 6596 Downloads 203
Srikanta Banerjee, Johns Hopkins School of Global Health, Baltimore, United States; Faculty Member, University of Roehampton Health Sciences, London, UK; Faculty Member, University of New England College of Graduate and Professional Studies, Portland, United States
Aaron Kaviani, Campbell Health and Education, Ontario, Canada
Prostate cancer, according to the World Health Organization, is the second most common cause of cancer worldwide. With an estimated 1.1 million people affected by prostate cancer in 2012, composing 15% of all new cancer cases worldwide, this condition poses a significant burden of mortality and morbidity on society. Even though the burden of prostate cancer is present worldwide, there are disparities in mortality rates worldwide. While in Sub-Saharan Africa and Caribbean, the age-adjusted mortality rates are as high as 24 per 100,000, in Asia the age-adjusted mortality rates are as low 2.9 per 100,000. Specific countries in Sub-Saharan Africa like Uganda have a prostate cancer mortality rate as high as 38.8 per 100,000, which is close to the incidence rate of 48.2 per 100,000. Even though in the United Kingdom the incidence rate is much higher at 111.1 per 100,000, the mortality rate is comparable to that of Sub-Saharan Africa at 22.8 per 100,000. As demonstrated in this global review of prostate cancer, the age-adjusted incidence rate and mortality rate are closer together in Sub-Saharan Africa than in high income countries. Also, there are disparities in age-adjusted mortality rates of prostate cancer. There is plausibly a large gap in data on incidence and mortality rates of prostate cancer, leading to potential underreporting of incidence rates. There are also different awareness related gaps in developing and developed countries. Improved surveillance systems need to be established in order to improve early detection screening programs and prioritized interventions for evidence-based policy for prostate cancer in all countries.
Worldwide Prostate Cancer Epidemiology: Differences Between Regions, Races, and Awareness Programs, International Journal of Clinical and Experimental Medical Sciences.
Vol. 2, No. 1,
2016, pp. 1-6.
Verma M, Patel P, Verma M. Biomarkers in prostate cancer epidemiology. Cancers. 2011; 3(4):3773-3798. doi: 10.3390/cancers3043773.
Routh J, Leibovich B. Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. Mayo Clinic Proceedings. 2005; 80(7):899-907.
Littman A, White E, Kristal A. Anthropometrics and prostate cancer risk. American Journal of Epidemiology. 2007; 165(11):1271-1279.
Gondos A, Krilaviciute A, Smailyte G, Ulys A, Brenner H. Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme. European Journal of Cancer. 2015; 51(12):1630-1637. doi: 10.1016/j.ejca.2015.04.009.
Neppl-Huber C, Zappa M, Coebergh JW, et al. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. Annals Of Oncology: Official Journal Of The European Society For Medical Oncology / ESMO. 2012; 23(5):1325-1334. doi: 10.1093/annonc/mdr414.
Kimura T. East meets West: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians. Chinese Journal of Cancer. 2012; 31(9):421-429. doi: 10.5732/cjc.011.10324.
International Agency for Research on Cancer. EUCAN: Prostate cancer Factsheet. Lyon, France; 2015. http://eco.iarc.fr/eucan/CancerOne.aspx?Cancer=29&Gender=1. Accessed August 30, 2015.
Plata Bello A, Concepcion Masip T. Prostate cancer epidemiology. Archivos Españoles De Urología. 2014; 67(5):373-382.
Zhau HE, Li Q, Chung LWK. Interracial differences in prostate cancer progression among patients from the United States, China and Japan. Asian Journal of Andrology. 2013; 15(6):705-707. doi: 10.1038/aja.2013.86.
Ferlay J, Shin HR, Bray F, Forman D, Mathers CD, Parkin D. GLOBO-CAN 2012, Cancer Incidence and Mortality Worldwide: IARC Cancer-Base No.10 [Internet]. Lyon, France: International Agency for Research on Cancer. 2015; Available from: http://globocan.iarc.fr.
Canadian Cancer Society. Prostate cancer statistics at a glance. Toronto, ON: Canadian Cancer Society; 2015. http://www.cancer.ca/en/cancer-information/cancer-type/prostate/statistics/?region=sk. Accessed 15 August 2015.
National Cancer Institute. SEER Stat Facts: Prostate cancer. Bethesda, MD: National cancer institute; 2015. http://seer.cancer.gov/statfacts/html/prost.html. Accessed August 2015.
Kaviani A, Fleshner N, Hosseini J. Epidemiology and etiology, chemoprevention.In: Kaviani A, Fleshner N, Hosseini J. Prostate Cancer. 2013 ed. Toronto: Campbell Health and Education Inc.; 2013. 1-14.
Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: Geographical distribution and secular trends. Mol Nutr Food Res. 2009; 53(2): 171-184. doi: 10.1002/mnfr.200700511.
Trinchieri A, Moretti R. Trends in prostate cancer epidemiology in the year 2000. Archivio Italiano Di Urologia, Andrologia: Organo Ufficiale [Di] Società Italiana Di Ecografia Urologica E Nefrologica / Associazione Ricerche In Urologia. 2005; 77(3):164-166.
Bono AV. The global state of prostate cancer: epidemiology and screening in the second millennium. BJU International. 2004; 94 Suppl 3:1-2.
Ahmed HU, Akin O, Coleman JA, et al. Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU International. 2012; 109(11):1636-1647. doi: 10.1111/j.1464-410X.2011.10633.x.
Hassen WA, Karsan FA, Abbas F, et al. Modification and implementation of NCCN guidelines on prostate cancer in the Middle East and North Africa region. Journal of The National Comprehensive Cancer Network: JNCCN. 2010; 8Suppl3:S26-S28.
Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H. Part I: Cancer in Indigenous Africans--burden, distribution, and trends. Lancet Oncol. 2008; 9(7):683-692.
Giovannucci E. Commentary: Serum lycopene and prostate cancer progression: a re-consideration of findings from the prostate cancer prevention trial. Cancer Causes & Control: CCC. 2011; 22(7):1055-1059. doi: 10.1007/s10552-011-9776-x.
Portela-Pereira P, Gómez-Veiga F. [What has changed in the epidemiology and screening of prostate cancer?]. Archivos Españoles De Urología. 2015; 68(3):202-209.
Ferlay J, Parkin DM, Curado MP, Bray F, Edwards B, Shin HR, et al. Cancer Incidence in Five Continents, Vol. 1-10. IARC Cancer Base No. 10. Lyon, France: International Agency for Research on Cancer; 2012. Available from: http://ci5.iarc.fr/CI5-X/Default.aspx.
Nakandi H, Kirabo M, Semugabo C, et al. Knowledge, attitudes and practices of Ugandan men regarding prostate cancer. African Journal of Urology. 2013; 19(4):165-170. doi: 10.1016/j.afju.2013.08.001.
Kabore FA, Kambou T, Zango B, Ouédraogo A. Knowledge and awareness of prostate cancer among the general public in Burkina Faso. J Cancer Educ. 2014; 29(1):69-73. doi: 10.1007/s13187-013-0545-2.
Gigerenzer G, Mata J, Frank R. Public Knowledge of Benefits of Breast and Prostate Cancer Screening in Europe. JNCI J Natl Cancer Inst. 2009; 101(17):1216-1220. doi: 10.1093/jnci/djp237.
Owens OL, Jackson DD, Thomas TL, Friedman DB, Hébert JR. Prostate Cancer Knowledge and Decision Making Among African-American Men and Women in the Southeastern United States. International journal of men’s health. 2015; 14(1): 55.